The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival analysis by pooling risk factors in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo (pla) in patients (pts) with advanced gastric cancer (AGC).
Y. Kang
Consultant or Advisory Role - Roche (U)
Honoraria - Roche
A. Ohtsu
No relevant relationships to disclose
E. Van Cutsem
Consultant or Advisory Role - Roche (U)
Research Funding - Roche
L. Roman
No relevant relationships to disclose
J. Nunes
No relevant relationships to disclose
C. Li
No relevant relationships to disclose
D. Otero
No relevant relationships to disclose
F. Rivera
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
G. Aprile
No relevant relationships to disclose
P. R. Pimentel Alvarez
No relevant relationships to disclose
M. H. Moehler
Consultant or Advisory Role - Roche
Honoraria - Roche
J. Wu
Employment or Leadership Position - Roche
B. Langer
Employment or Leadership Position - Roche
M. A. Shah
Research Funding - Roche; Sanofi